Skip to content

Procalcitonin and Threatened Premature Delivery

Procalcitonin and Threatened Premature Delivery

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01977079
Acronym
MAPPRO
Enrollment
131
Registered
2013-11-06
Start date
2013-12-31
Completion date
2016-07-31
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Premature Delivery

Keywords

pregnancy, premature birth, procalcitonin

Brief summary

Among all patients hospitalized for Threatened Premature Delivery (TPD), the rate of premature birth (PB) before 37 weeks is about 42%, which reflects the inability to accurately identify patients at high risk of PB. Currently, no clinical or biological marker is recognized as the most reliable in predicting the real risk of AP in case of MAP. The purpose of this study is to improve the knowledge of predictors of preterm delivery compared with conventional blood markers by estimating serum procalcitonin according to premature delivery or not in patients hospitalized for preterm labor .

Interventions

OTHERprocalcitonin

Sponsors

Centre Hospitalier Departemental Vendee
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 year * Ongoing pregnancy with a start date of pregnancy known and confirmed by an ultrasound of the 1st Quarter performed between 10 and 14 weeks with a measurement of the crown-rump length * hospitalization for preterm labor between 24 and 36 weeks of gestation * Intact membranes, * not opposed to participate in the study

Exclusion criteria

* Pregnancy uncertain term (no early ultrasound) * Pregnancy combining a condition that can interfere with the assays performed, * Uterine malformation known * Multiple pregnancy, * Premature rupture of membranes, * Chrorio-amnionitis, * Fetal malformation known * Strapping * GB\> 15000 and CRP\> 10 mg / L, * No affiliation to a social security scheme. * Woman with a measure of legal protection

Design outcomes

Primary

MeasureTime frameDescription
procalcitonin rateup to 48 hoursEstimate serum procalcitonin according to premature or not in patients hospitalized for preterm labor.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026